The plant has been operating at 100 percent since this summer, but to boost its overall supply, the world’s main contrast dye supplier invested $80 million into increasing its contrast media production by 30 percent at its site in Lindesnes, Norway. The company planned the investment because of the predicted surge in global demand.
Kevin O’Neill, the president and CEO of GE Healthcare’s pharmaceutical diagnostics division, said in a statement the company expects demand for the product to double in the next 10 years because of the “global prevalence of chronic disorders and significant growth in CT procedures.”
Annually, healthcare providers perform about 300 million CT scans, but this was hindered during the summer after one facility closed, highlighting the vulnerability of the global supply of the iodine solution.
GE Healthcare said it plans to boost its contrast dye supply by 30 million more doses by 2025.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.